Nama's AI scorecard currently rates BioMarin Pharmaceutical Hold (5.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is BMRN's P/E ratio?

BioMarin Pharmaceutical trades at a trailing price-to-earnings ratio of 21.1.

When does BMRN report earnings?

BioMarin Pharmaceutical's next scheduled report is on Feb 22, 2027. Analysts expect EPS of -$0.11.

What is the BMRN price target?

The median analyst price target from 27 analysts is $90.00, with a range of $60.00 – $120.00.

Is BMRN Shariah compliant?

Nama's AAOIFI-style screen reads BioMarin Pharmaceutical as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

BioMarin Pharmaceutical (BMRN)

Healthcare · Biotechnology · NASDAQ

BioMarin Pharmaceutical (BMRN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $10.85B, a trailing price-to-earnings ratio of 21.1 and a free-cash-flow yield of 6.5%. Over the most recent reported fiscal year, revenue grew 12.9% and free cash flow per share grew 50.3%. Nama's AI scorecard rates it Hold, 5.3 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 5.3/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +6.5% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-52.4%

How far the last close sits under the highest price of the past five years.

Market cap	$10.85B
Trailing P/E	21.1
Price / book	1.7
Price / sales	3.2
FCF yield	6.5%
Dividend yield	—
Gross margin	76.1%
Operating margin	4.4%
Net margin	2.1%
Revenue growth (YoY)	+12.9%
Revenue growth (3-yr annual)	+15.4%
EPS growth (YoY)	-10.0%
FCF/share growth (YoY)	+50.3%
Beta	0.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

BMRN earnings

Next report: Feb 22, 2027 (Q4 2026, EPS estimate -$0.11). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$0.23	-$0.11	+309.1%	$1.02B
Q2 2026	Aug 6, 2026	$1.20	$0.95	+26.3%	$989.71M
Q1 2026	May 4, 2026	$0.76	$0.91	-16.5%	$766.21M
Q4 2025	Feb 23, 2026	$0.46	$0.56	-17.9%	$874.57M

BMRN analyst price target

Median target $90.00 from 27 analysts, ranging $60.00 – $120.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live BMRN data on Nama Insights →

BMRN FAQ

Is BMRN a buy?: Nama's AI scorecard currently rates BioMarin Pharmaceutical Hold (5.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BMRN's P/E ratio?: BioMarin Pharmaceutical trades at a trailing price-to-earnings ratio of 21.1.
When does BMRN report earnings?: BioMarin Pharmaceutical's next scheduled report is on Feb 22, 2027. Analysts expect EPS of -$0.11.
What is the BMRN price target?: The median analyst price target from 27 analysts is $90.00, with a range of $60.00 – $120.00.
Is BMRN Shariah compliant?: Nama's AAOIFI-style screen reads BioMarin Pharmaceutical as Not Shariah Compliant. At least one of the three ratios or the industry test failed.